DE69940371D1 - Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline - Google Patents

Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Info

Publication number
DE69940371D1
DE69940371D1 DE69940371T DE69940371T DE69940371D1 DE 69940371 D1 DE69940371 D1 DE 69940371D1 DE 69940371 T DE69940371 T DE 69940371T DE 69940371 T DE69940371 T DE 69940371T DE 69940371 D1 DE69940371 D1 DE 69940371D1
Authority
DE
Germany
Prior art keywords
beta
containing compositions
specific immunoglobulins
glucan containing
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69940371T
Other languages
English (en)
Inventor
Viliam Pavliak
Ali Ibrahim Fattom
Robert B Naso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nabi Biopharmaceuticals Inc
Original Assignee
Nabi Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals Inc filed Critical Nabi Biopharmaceuticals Inc
Application granted granted Critical
Publication of DE69940371D1 publication Critical patent/DE69940371D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69940371T 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline Expired - Lifetime DE69940371D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10014698P 1998-09-14 1998-09-14
PCT/US1999/020787 WO2000015238A1 (en) 1998-09-14 1999-09-14 COMPOSITIONS OF β-GLUCANS AND SPECIFIC IGIV

Publications (1)

Publication Number Publication Date
DE69940371D1 true DE69940371D1 (de) 2009-03-19

Family

ID=22278313

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940371T Expired - Lifetime DE69940371D1 (de) 1998-09-14 1999-09-14 Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline

Country Status (11)

Country Link
US (1) US6355625B1 (de)
EP (1) EP1121135B1 (de)
AT (1) ATE421883T1 (de)
AU (1) AU6033299A (de)
CA (1) CA2344166C (de)
CY (1) CY1109437T1 (de)
DE (1) DE69940371D1 (de)
DK (1) DK1121135T3 (de)
ES (1) ES2321892T3 (de)
PT (1) PT1121135E (de)
WO (1) WO2000015238A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6756361B1 (en) * 1997-10-14 2004-06-29 Nabi Enterococcus antigens and vaccines
US7030101B2 (en) * 1998-09-14 2006-04-18 Nabi Biopharmaceuticals Compositions of β-glucans and specific antibodies
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
EP1357919B1 (de) * 2001-01-16 2017-04-05 Sloan-Kettering Institute For Cancer Research Glucan zur verbesserung der therapie
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
JP2006502167A (ja) 2002-09-04 2006-01-19 バイオポリマー エンジニアリング，インコーポレイテッド 全グルカン粒子および抗体を用いた癌治療
US20090169557A1 (en) * 2004-05-10 2009-07-02 Biopolymer Engineering, Inc. D/B/A Biothera Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies
US20080095777A1 (en) 2004-09-22 2008-04-24 Glaxosmithkline Biologicals S.A. Immunogenic Composition for Use in Vaccination Against Staphylococcei
US20060134141A1 (en) * 2004-12-14 2006-06-22 Nabi Biopharmaceuticals Glycoconjugate vaccines containing peptidoglycan
AU2005324448A1 (en) * 2005-01-10 2006-07-20 Glaxosmithkline Biologicals Sa Method of treating Staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
US20090214562A1 (en) * 2005-05-03 2009-08-27 Karel Steven J Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
JP5296531B2 (ja) * 2005-05-05 2013-09-25 センシエント フレイバーズ エルエルシー βグルカン及びマンナンの製造
CA2611023A1 (en) 2005-06-13 2006-12-21 Nabi Biopharmaceuticals Use of panton-valentine leukocidin for treating and preventing staphylococcus infections
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
US8323644B2 (en) 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
JP2009531387A (ja) 2006-03-30 2009-09-03 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
WO2007145689A1 (en) 2006-06-12 2007-12-21 Nabi Biopharmaceuticals Use of alpha-toxin for treating and preventing staphylococcus infections
EP2208787A1 (de) 2009-01-19 2010-07-21 Université de Liège Rekombinantes alpha-Hämolysin-Polypeptid von Staphylococcus aureus, mit einer Deletion in der Stammdomäne und eingefügten heterologen Sequenzen
US20100260752A1 (en) 2009-01-23 2010-10-14 Biosynexus Incorporated Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria
WO2011005341A2 (en) 2009-04-03 2011-01-13 University Of Chicago Compositions and methods related to protein a (spa) variants
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
PL3444268T3 (pl) 2010-05-05 2022-04-19 New York University Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
EP2614074A1 (de) 2010-09-09 2013-07-17 The University of Chicago Verfahren und zusammensetzungen mit schützenden staphylokokken-antigenen
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
ES2812181T3 (es) 2011-06-19 2021-03-16 Univ New York Métodos de tratamiento y prevención de infecciones por staphylococcus aureus y afecciones asociadas
BR112013032911A2 (pt) 2011-06-19 2017-01-24 Univ New York leucotoxina e/d como um novo agente anti-inflamatório e microbicida
CN103906535B (zh) 2011-08-15 2017-07-14 芝加哥大学 与葡萄球菌蛋白a的抗体相关的组合物和方法
JP6670106B2 (ja) 2012-04-26 2020-03-18 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ ブドウ球菌コアグラーゼ抗原およびその使用方法
JP6251730B2 (ja) 2012-04-26 2017-12-20 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法
JP6416751B2 (ja) * 2012-04-30 2018-10-31 バイオセラ インコーポレイテッド β−グルカン免疫治療方法
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
AU2015359503B2 (en) 2014-12-10 2019-05-09 Glaxosmithkline Biologicals Sa Method of treatment
EP3416979A4 (de) 2016-02-12 2019-09-11 The University of Chicago Zusammensetzungen und verfahren in zusammenhang mit antikörpern zur neutralisierung der koagulaseaktivität bei einer staphylococcus-aureus-erkrankung
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
BR112022005615A2 (pt) 2019-10-02 2022-07-12 Janssen Vaccines & Prevention Bv Peptídeos de staphylococcus e métodos de uso
WO2023192998A1 (en) 2022-04-01 2023-10-05 Icahn School Of Medicine At Mount Sinai Treating orthopedic injury with a vector driving expression of acid ceramidase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4739046A (en) * 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
CA2040374C (en) * 1990-07-06 1998-06-16 Gunnar Rorstad Process for enhancing the resistance of aquatic animals to disease
EP0648127B1 (de) * 1991-11-22 2003-04-16 Univax Biologics Incorporated Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
WO1996014873A2 (en) 1994-11-16 1996-05-23 Sri International COVALENTLY BOUND β-GLUCAN CONJUGATES IN TARGETED DELIVERY
US5785975A (en) * 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5770208A (en) * 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen

Also Published As

Publication number Publication date
CY1109437T1 (el) 2014-08-13
WO2000015238A9 (en) 2000-10-12
WO2000015238B1 (en) 2000-08-31
EP1121135A4 (de) 2005-03-16
EP1121135A1 (de) 2001-08-08
ATE421883T1 (de) 2009-02-15
EP1121135B1 (de) 2009-01-28
WO2000015238A1 (en) 2000-03-23
PT1121135E (pt) 2009-03-05
US6355625B1 (en) 2002-03-12
CA2344166A1 (en) 2000-03-23
CA2344166C (en) 2008-11-18
AU6033299A (en) 2000-04-03
DK1121135T3 (da) 2009-03-23
ES2321892T3 (es) 2009-06-12

Similar Documents

Publication Publication Date Title
DE69940371D1 (de) Beta-glucan enthaltende zusammenstellungen und spezifische immunoglobuline
BR9917152A (pt) Composição para tratamento terapêutico ou profilático de infecção estreptocócica e método e uso respectivos
NO965378D0 (no) Pyrazolo- og pyrolopyridiner
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
TR200000059T2 (tr) Piridin türevleri
DE60005953D1 (de) Stapelbare statische mischelemente
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
TR199900856T2 (xx) Bron�la ilgili terapi maddeleri olarak benzonaftiridinler
DE69928952D1 (de) Chinolin-derivate und ihre verwendung als antibakterielle wirkstoffe
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
DE60043868D1 (de) Abgeschwächte Mikroorganismen für die Behandlung von Infektionen
DE60033649D1 (de) Verbindungen und therapeutische methoden
ATE199321T1 (de) Anti idiotypische antikörper gegen gonococcen und diese verwendende verfahren und zusammensetzungen.
DK1042492T3 (da) Humaniserede monoklonale antistoffer der beskytter med Shiga-toksininducerede sygdomme
EA200100700A1 (ru) Гены и белки и их применение
BRPI0413684A (pt) compostos, composição farmacêutica e respectivos métodos de preparação, de tratamento de infecção microbiana e de extermìnio de microrganismo e usos
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE69931784D1 (de) Chemotaxis hemmendes protein von staphylococcus aureus (chips) und dessen verwendung
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
ATE108832T1 (de) Verwendung von monoklonalen antikörpern gegen b2- mikroglobulin.
ATE212839T1 (de) Hämoregulatorische verbindungen
IT1276454B1 (it) Metodo per la diagnosi di infezioni helycobacter pylori e relativo corredo diagnostico.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition